
51 - 200 employees
🧬 Biotechnology
💊 Pharmaceuticals
🏥 Healthcare
💰 $25M Post-IPO Equity on 2022-04
Biotechnology • Pharmaceuticals • Healthcare
Zentalis Pharmaceuticals is developing potentially best-in-class, novel small molecules that target fundamental biological pathways in cancer. The company focuses on creating therapeutics aimed at treating various forms of cancer by leveraging innovative approaches in biotechnology.
🔥 2 hours ago
Senior Medical Science Liaison supporting Zentalis’s ovarian cancer and tumor therapies. Building scientific relationships, communicating clinical data, and supporting trials across the United States.